Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
Article has an altmetric score of 3

See more details

Referenced in 1 policy sources
14 readers on Mendeley
  • Article usage
  • Citations to this article (133)

Advertisement

Research Article Free access | 10.1172/JCI107014

Inhibition of thyrotropin response to thyrotropin-releasing hormone by small quantities of thyroid hormones

Peter J. Snyder and Robert D. Utiger

1Endocrine Section, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104

Find articles by Snyder, P. in: PubMed | Google Scholar

1Endocrine Section, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104

Find articles by Utiger, R. in: PubMed | Google Scholar

Published August 1, 1972 - More info

Published in Volume 51, Issue 8 on August 1, 1972
J Clin Invest. 1972;51(8):2077–2084. https://doi.org/10.1172/JCI107014.
© 1972 The American Society for Clinical Investigation
Published August 1, 1972 - Version history
View PDF
Abstract

Inhibition of thyrotropin (TSH) release by chronic treatment with small quantities of triiodothyronine (T3) and thyroxine (T4) was evaluated by determining the serum TSH response to thyrotropin-releasing hormone (TRH) in normal subjects and hypothyroid patients. Response to TRH was determined before treatment and after each dosage of a synthetic combination of T3 + T4 had been given for 3-4 wk.

Treatment of eight normal subjects with 15 μg T3 + 60 μg T4 reduced the maximum increase in serum TSH above baseline (maximum ΔTSH) by 76% in response to 400 μg TRH and by 87% in response to 25 μg TRH. The average serum T3 level during a 24 hr period in normal subjects who had been taking 15 μg T3 + 60 μg T4 for 3-4 wk was 129±10 ng/100 ml (mean ±SEM), well within the normal range, 70-150 ng/100 ml, although higher than the pretreatment level, 98±7 ng/100 ml. The average serum T4 level was unchanged from the pretreatment level. Treatment of the same subjects with 30 μg T3 + 120 μg T4 reduced the maximum ΔTSH further.

Six patients with primary hypothyroidism were treated, sequentially, with 15 + 60, 22.5 + 90, and 30 μg T3 + 120 μg T4. For each patient there was one increase in dosage of 7.5 μg T3 + 30 μg T4 which abruptly converted a maximum ΔTSH that was greater than, or at the upper limit of, normal to one that was subnormal. Concurrent with these six abrupt changes in TSH response, the mean serum T3 level increased only from 105±5 to 129±9 ng/100 ml, and the mean serum T4 level increased only from 4.9±0.8 to 6.3±0.5 μg/100 ml.

These data demonstrate the extreme sensitivity of TRH-induced TSH release to inhibition by the chronic administration of quantities of T3 + T4 which do not raise serum T3 and T4 levels above the normal ranges.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 2077
page 2077
icon of scanned page 2078
page 2078
icon of scanned page 2079
page 2079
icon of scanned page 2080
page 2080
icon of scanned page 2081
page 2081
icon of scanned page 2082
page 2082
icon of scanned page 2083
page 2083
icon of scanned page 2084
page 2084
Version history
  • Version 1 (August 1, 1972): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

Article has an altmetric score of 3
  • Article usage
  • Citations to this article (133)

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 1 policy sources
14 readers on Mendeley
See more details